Eli Lilly 3Q 2026: Revenue $24.4B, Net income $6.45B, EPS $7.22— 10-Q Summary
Eli Lilly reported 3Q 2026 revenue of $24.4B, up 38.6% YoY, with net income at $6.45B (15.5% increase) and EPS at $7.22 (16.3% increase). Growth was driven by higher volume, partially offset by lower prices. Key products Mounjaro, Zepbound, and Foundayo contributed 66% of revenue in the first nine months. The company received FDA approvals for Foundayo, Onswik, and tirzepatide.
How this was made
The 30-second read
Why it matters
Traders can use the reported revenue/EPS figures and the listed FDA approvals and Phase 3 endpoint progress to reassess near-term fundamentals and risk around pricing and payer access.
Market read
Fresh quarterly financials plus FDA approvals and Phase 3 endpoint confirmation create a direct catalyst set for LLY positioning, while pricing and Medicare access uncertainty remain key risk variables.
What to watch
Lower realized prices and the uncertainty around Medicare pricing-policy effects may be more important for margin trajectory than volume growth alone.
Background
The piece is an AI summary of Eli Lilly’s Oct. 29, 2026 SEC 10-Q, covering 3Q 2026 financials and several pipeline and regulatory milestones.
Ticker impact
Eli Lilly’s 3Q 2026 10-Q reports $24.4B revenue, $6.45B net income, and EPS $7.22, plus FDA approvals and trial progress.
Likely upward bias as investors focus on revenue growth and multiple FDA approvals, tempered by concerns about pricing pressure and uncertain Medicare uptake effects.
The article provides fresh quarterly financial datapoints and new FDA approval and Phase 3 endpoint information, which are direct drivers for near-term sentiment and forward expectations.
Market effects
Reinforces the GLP-1 obesity/diabetes competitive narrative, with pricing and payer access (Medicare bridge) remaining key swing factors for the group.
Primarily US-focused via Medicare access and FDA approvals, which can influence US managed-care and formulary expectations.
US regulatory and payer-access developments can spill over into global sentiment for GLP-1 manufacturers, even if approvals are US-specific.
Counterpoint
The headline growth may be partially offset by pricing pressure, and Medicare discounted access uptake is explicitly uncertain, which could cap multiple expansion despite strong top-line growth.
Key entities
- companyEli Lilly and Company
Subject of the 10-Q summary, reporting 3Q 2026 financial results and multiple FDA and clinical-trial updates.
- productMounjaro
GLP-1 franchise product cited as a revenue growth driver.
- productZepbound
GLP-1 franchise product cited as a revenue growth driver.
- productFoundayo
FDA-approved for obesity in the article’s business highlights.
- productOnswik
FDA-approved for type 2 diabetes in the article’s business highlights.
